Who should be Prioritized for COVID-19 Vaccination in China? A Descriptive Study

Juan Yang¹, Wen Zheng¹, Huilin Shi¹, Xuemei Yan¹, Kaige Dong¹, Qian You¹, Guangjie Zhong¹, Hui Gong¹, Zhiyuan Chen¹, Mark Jit²,³,⁴, Cecile Viboud⁵, Marco Ajelli⁶,⁷, Prof Hongjie Yu¹

Corresponding author to Prof. Hongjie Yu, yhj@fudan.edu.cn

Affiliations:
1. School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
2. Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
3. Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
4. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
5. Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
6. Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA
7. Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University, Boston, MA, USA

Abstract
All countries are facing decisions about which groups to prioritise for COVID-19 vaccination after the first vaccine product has been licensed, at which time supply shortages are inevitable. Here we define the key target populations and their size in China for a phased introduction of COVID-19 vaccination with evolving goals, accounting for the risk of illness and transmission. Essential workers (47.2 million) like healthcare workers could be prioritized for vaccination to maintain essential services. Subsequently, older adults, individuals with underlying health conditions and pregnant women (616.0 million) could be targeted to reduce severe COVID-19 outcomes. Then it could be further extended to target adults without underlying health conditions and children (738.7 million) to reduce symptomatic infections and/or to stop virus transmission. The proposed framework could assist Chinese policy-makers in the design of a vaccination program, and could be generalized to inform other national and regional COVID-19 vaccination strategies.

Key words: Novel coronavirus diseases 2019; vaccination; target population; China

This study does not necessarily represent the views of the US government or the National Institutes of Health.
Abstract (words): 148

Main text (words): 4,302

Running head: Priority populations for COVID-19 vaccination in China
Introduction

Coronavirus disease 2019 (COVID-19) pandemic is causing unprecedented impact on global health and the economy. In the absence of safe and highly effective vaccines and treatment options, non-pharmaceutical interventions are used to decrease transmission and reduce the burden of COVID-19 but most of these interventions have large economic costs. Effective vaccines against COVID-19 are urgently needed to reduce the significant burden of COVID-19 morbidity and mortality. Globally, there are over 300 vaccine candidates at various stages of development in the research pipeline. Of these, over 30 candidates have entered clinical trials.

On June 26, 2020, the World Health Organization (WHO) unveiled a plan to deliver 2 billion doses of COVID-19 vaccines, of which 50% will go to low-and-middle income countries, by the end of 2021. Currently, the projected global production capacity is inadequate to provide COVID-19 vaccines for every human being on the planet, particularly immediately after the first vaccine has been licensed. It is possible that countries and entire regions will have no access to vaccines. For example, COVID-19 cases are rapidly increasing in most African countries. However, none of the COVID-19 vaccine candidates is being developed by an African manufacturer. Even if a vaccine were available, many low-income countries would have to rely on vaccines manufactured abroad. Hence national and multinational vaccine producers will need to allocate a proportion of their production to countries that do not have the financial ability to pre-order vaccine doses that are still to be licensed. Setting priorities for target populations to be vaccinated and optimizing resources within and between countries entails difficult choices. Nonetheless, this is critical for a successful global pandemic vaccination program, and this needs to be addressed urgently.

China was the first country to face the COVID-19 pandemic, although only Wuhan, in Hubei Province, was hit by a major wave of infections. Nearly the entire population of mainland China (~1.4 billion people) is still susceptible to COVID-19. Recent surges of COVID-19 cases occurred separately in Beijing, Dalian, and Urumchi after one or more months without any report of
locally-acquired infections. There is a risk of a new major wave of COVID-19, especially after the economy and society have re-opened both domestically and abroad.

China has invested substantial resources in vaccines and is one of the main actors in the race to develop a vaccine to help control the COVID-19 pandemic, with resources provided by government, manufacturers and non-governmental organizations. Over ten vaccine candidates are being developed in mainland China; three of them (developed by Sinovac Instituto Butantan, Wuhan Institute of Biological Products/Sinopharm, and Beijing Institute of Biological Products/Sinopharm) are in phase III trials as of August 13, 2020. New COVID-19 vaccine production facilities recently completed or currently under construction are expected to have the capacity to produce 1 billion doses annually. However, the output is far behind the quantity needed to vaccinate a population of nearly 1.4 billion people in mainland China alone (given a two-dose schedule for all vaccine candidates). Hence, there is a need to establish priority target populations for a COVID-19 vaccination program. This study aims to define the key target populations, their size, and priority for a phased introduction of COVID-19 vaccination with evolving goals, accounting for risk of severe illness and transmission. This approach is generalizable to inform national and regional strategies for the use of COVID-19 vaccines, especially in low-and-middle income countries.

Results

For a phased COVID-19 vaccination program, the most important objective (primary goal) of the vaccination program is to maintain essential services (e.g., healthcare and national security) in the early phase. The second objective (secondary goal) is to reduce the number of individuals with severe outcomes, including hospitalizations, critical care admissions, and deaths. In later stages, the objective of the vaccination program can be further extended to reduce symptomatic infections and/or to stop virus transmission (tertiary goal). Subsequently, these population groups were categorized into six vaccination tiers in order of decreasing priority. Figure 1 illustrates the priority population groups relevant for each goal and the corresponding population size estimated.
without excluding duplicates between groups.

**Essential workers**

It is important to stress that the vaccine may be in extremely short supply when first available. To meet the primary goal of vaccination, thus it could be necessary to consider healthcare workers as the top priority (Tier 1 of the vaccination strategy) based on utilitarian (i.e. maximizing health and economic benefit) and egalitarian (i.e. protecting the worst off) principles. Law enforcement and security workers, personnel in nursing home and social welfare institutes, community workers, workers in energy, food and transportation sectors are included in Tier 2 based on utilitarian principles (Figure 1). We estimated that in mainland China there are 10.7 million healthcare workers, 4.4 million people working in law enforcement agencies and security personnel, 0.4 million personnel in nursing home and social welfare institutes, 4.5 million community workers, and 27.3 million workers in the energy, food, and transportation sectors.

**High-risk individuals**

As of August 12, 2020, a total of 76 systematic reviews reported the pooled risk of severe outcome of COVID-19, including hospitalizations, critical care admissions, and deaths. Among them, 55 (72%) were peer-reviewed and published. 71% (54/76) of systematic reviews evaluated the quality of included original articles, and reported that the majority of included studies were of moderate-to-high quality. (Supplementary Materials Table S1, and Figure S1-S2)

The published systematic reviews showed that increased risk of severe outcomes from SARS-CoV-2 infection were observed in individuals with chronic respiratory disease including but not limited to chronic obstructive pulmonary diseases (38 of 43 papers report significant association, OR/RR: mean 1.53-17.80), heart disease (3 of 3 papers, 2.03-4.09), cardio-cerebrovascular disease (22 of 25 papers, 1.44-36.88), hypertension (26 of 26 papers, 1.66-5.34), diabetes (28 of 30 papers, 1.39-4.64), chronic renal diseases (8 of 9 papers, 1.84-9.41), chronic liver disease (3 of 9
papers, 1.48-2.69), cancer (14 of 17 papers, 1.56-4.86), and obesity (5 of 7 papers, 1.21-3.68)\textsuperscript{14-66} (Supplementary Materials Figure S1). Only one systematic review evaluated the disease severity of COVID-19 during pregnancy, and found that 21% were severe/critical cases.\textsuperscript{67} COVID-19 may cause fetal distress, miscarriage, respiratory distress and preterm delivery, although evidence for these associations is still inconclusive.\textsuperscript{68} Moreover, pregnant women have high frequency of antenatal care visits and thus have a possibly higher exposure to SARS-CoV-2. Although no systematic review found a significantly higher risk of severe outcomes for those with immunodeficiency/immunosuppression, chronic neurological disorders, and sickle cell disorders, we included these categories in our analysis as recommended by the US and UK.\textsuperscript{27,69-71}

Age is one of the most important risk factors for severe/fatal COVID-19. Our systematic reviews showed that individuals age $\geq 60$ years had about 4-fold higher risk of severe/fatal COVID-19 than younger people (Supplementary Materials, Figure S1-S2). Wu et al. found that the case-fatality risk for those aged $\geq 80$ years was 1.7-3.6 times that among those aged 70-79, and 60-69 years.\textsuperscript{72} Age and underlying conditions combine to increase the risk.\textsuperscript{73} Accordingly, adults $\geq 60$ years of age with underlying conditions, and adults $\geq 80$ years of age without underlying conditions, who are at the highest risk of severe/fatal COVID-19, were considered in Tier 3, based on egalitarian principles. Compared to these persons, the risk of severe/fatal COVID-19 among older adults aged 60-79 years without underlying conditions and individuals $< 60$ years of age with underlying conditions was lower. These individuals aged $< 60$ years with pre-existing medical conditions and pregnant women were included in Tier 4 based on egalitarian principles (Figure 1).

We estimated that 363.3 million individuals aged $< 60$ years and 158.1 million individuals aged $\geq 60$ years had at least one high-risk medical condition in mainland China. The number of pregnant women was thus estimated at 26.3 million in mainland China (Figure 1).

**Individuals at high risks of symptomatic COVID-19 infections**
Population-based studies demonstrated that the incidence of COVID-19 cases in those aged 20-59 years was similar to that among older adults.\textsuperscript{6,74} (Supplementary Materials Table S2-S3). Our meta-analysis showed the cumulative incidence was 139-161 per 100,000 persons among those aged 20-59 years, which was comparable to incidence in those aged ≥ 60 years (195 per 100,000 persons) (Figure 2). These working age adults had a higher risk of acquiring COVID-19 symptomatic infection possibly because of their large number of contacts at work and in the community.\textsuperscript{75} Additionally, they contribute to maintenance of societal functions and economic well-being; and they generally provide care for children. Given these considerations, individuals aged 20-59 years without underlying conditions (n=551.3 million) were included in Tier 5 based on both utilitarian and egalitarian principles (Figure 1).

Population-based sero-epidemiological studies also reported lower seroprevalence in children than in adults.\textsuperscript{76,77} Whether this reflects lower susceptibility of children to infection in general, or similar infection rates, but much higher proportions with asymptomatic disease, or rather the effect of school closures, the implemented strict social distancing measures, or a self-protective behavior of the population remains unclear. Modeling studies found conflicting results about the effect of interventions targeted at children on SARS-CoV-2 transmission at the community level,\textsuperscript{78,79} suggesting that there is still uncertainty surrounding fundamental epidemiological parameters of COVID-19 related to children (e.g., their infectiousness,\textsuperscript{80,81} susceptibility to infection,\textsuperscript{82,83} and probability of developing symptoms).\textsuperscript{84} To ensure the continuity of educational activities, and reduce transmission, school-age children (n=190.2 million) are recommended for vaccination in Tier 6 based on both utilitarian and egalitarian principles (Figure 1).

The incidence of COVID-19 was lower in younger children. However, the severity among young children has not been fully addressed. Verdoni et al., reported an outbreak of a novel severe Kawasaki-like disease in children related to COVID-19 in Italy, which raised concerns about the impact of the pandemic on younger children.\textsuperscript{85} Considering such possible post-infectious inflammatory syndrome as Kawasaki-like disease, younger children aged ≤5 years (n=98.7...
million), which are priority groups for influenza vaccination, are recommended in Tier 6 as well, based on egalitarian principles of prioritizing the most vulnerable individuals (Figure 1).

Estimated size of target population of the phased universal vaccination program

To maintain essential societal functions, the target population of vaccination was estimated at 47.2 million (Tiers 1 and 2, Figure 1 and Figure 3). An additional 616.0 million persons were included in the target population if the goal of vaccination was extended to reduce the number of severe COVID-19 cases (Tiers 3 and 4, Figure 1 and Figure 3). Along with the increase of vaccine supply, the remaining 738.7 million persons could be further targeted for vaccination to reduce the total number of COVID-19 symptomatic cases and potentially halt transmission (Tiers 5 and 6, Figure 1 and Figure 3). In terms of vaccination tiers (from Tier 1 to Tier 6), a total of 10.7, 36.5, 163.3, 452.7, 502.5 and 236.2 million persons were included in the target population (Figure 4).

Given 3 million doses administered per day, and a two-dose vaccination schedule, it will likely take about 19 months to vaccinate 60% of the overall population. However, only three weeks would be required to vaccinate individuals working in critical infrastructure sectors (Tier 1 and 2), two months for Tier 3, six months for Tier 4, about seven months for Tier 5, and three months for Tier 6 (Figure 5). With an expected one billion doses produced per year,9–11, and given a fixed 60% uptake rate among Tiers, the estimated vaccine supply could cover individuals in Tier 1-3 and one fifth of individuals in Tier 4 given a two-dose vaccination schedule.

The sensitivity analyses show it will take two years to vaccinate 80% of individuals given 3 million doses administered each day; 3.5 years to vaccinate 60% of individuals given 1.3 million doses administered each day (Supplementary Materials, Figure S4-S6). It will take about one year and 10 months to vaccinate 80% and 60% of individuals respectively, if the capacity of COVID-19 vaccination delivery was scaled up to 6 million doses administered each day (Supplementary Materials, Figure S4-S6).
Discussion

In the absence of specific antiviral treatment for COVID-19, vaccination likely represents the most promising way to control the COVID-19 pandemic. However, even if a COVID-19 vaccine becomes available, initial supplies will inevitably be limited. Supply issues could persist in the long-term, due to huge global demand and limited production capacity. Almost everyone can potentially benefit from vaccination because of residual high susceptibility to SARS-CoV-2 infection. Considering different goals of a future vaccination program, changes in vaccine supplies, various levels of responsibility of population groups to the COVID-19 pandemic responses and essential services, as well as the risk of severe outcome and illness, we recommend a phased universal COVID-19 vaccination program for mainland China. Workers in critical sectors, including healthcare workers, law enforcement and security personnel, personnel in nursing home and social welfare institutes, as well as sectors of energy, water, food, and transportation (47.2 million) are the main candidates to receive high priority for vaccination, in order to maintain essential societal functions. Subsequently, we propose to extend the vaccination program to older adults, pregnant women, and those with underlying medical conditions (616.0 million), in order to reduce severe outcomes of COVID-19. Finally, working-age adults, school-age children and younger children (738.7 million) could be vaccinated in order to reduce symptomatic COVID-19 infections, and/or to stop SARS-CoV-2 transmission.

Target population groups are further grouped into vaccination tiers from 1 to 6, with Tier 1 having the highest priority. Even though individuals within a tier have equal priority for vaccination, it may be necessary to sub-prioritize vaccination of groups within a tier in case of extremely short initial vaccine supplies. For instance, meat and poultry processing facility workers, who have been particularly affected by COVID-19 and often linked to workplace transmission, could be vaccinated before other personnel in the food supply chain within Tier 2. Although other factors like smoking, being male, and being an ethnic minority were found to be risk factors of
severe outcome and deaths from COVID-19 in previous studies, they were not accounted for when determining priority population here due to consideration of equity and feasibility of vaccination.

The majority of the current COVID-19 vaccine candidates are being trialed as two dose schedules. A total of 57 million, 739 million and 886 million doses are separately needed to cover 60% of individuals in critical infrastructure sectors, persons at high risk of severe outcomes of COVID-19, and persons at high risk of acquiring symptomatic illness/infections. Between 2007 and 2015, the volume supplied of all vaccines (n=55) licensed in mainland China varied from 666 million doses to 1.19 billion doses per year. Several manufacturers state that a total of 1 billion doses of COVID-19 vaccine could be produced annually. This implies that the potential production capacity may be far behind the demand in mainland China given a two-dose schedule. This dilemma is likely not unique to China and other countries across the world, particularly in low-and-middle income regions, will face a similar challenge.

Even at the maximum rate at which H1N1pdm vaccines were delivered in 2009 (3 million doses administered each day), vaccinating 60% of the general population groups will take 1.5 years, without considering limits in production capacity. Such a large-scale vaccination program like COVID-19 could also represent a major challenge for current the National Immunization Program in China, which is currently focused on childhood vaccination rather than on adult vaccination. The limited production capacity will likely further delay COVID-19 vaccination programs.

Our study has a number of limitations. First, we have qualitatively discussed the segments of the population to be prioritized in a COVID-19 vaccination program as well as the rationale behind prioritization choices. However, we could not quantitatively examine whether prioritizing older adults to reduce severe outcomes is a better choice than prioritizing working-aged adults or school-age children to reduce illness/transmission. Mathematical modelling is urgently needed to
assess both the health and economic impacts of potential vaccination strategies, and the potential to reduce for herd immunity benefits. Second, we did not consider eligibility for vaccination due to lack of efficacy and/or safety concerns that may affect specific groups such as older adults, people with pre-existing medical conditions, pregnant women and very young children, since no vaccine has been licensed yet. Third, we did not consider real-time reactive outbreak immunization strategies because it is impossible to estimate the corresponding target population size. However, we strongly recommend use of COVID-19 vaccination during local outbreaks coupled with other non-pharmaceutical interventions in order to prevent subsequent waves of disease. Moreover, we did not discuss prioritization based on geography; the risk of COVID-19 exposure may be low in regions that have seen widespread COVID-19 activity by the time the vaccine is available and have a high level of population immunity. This may not be particularly relevant for China where the epidemic has been well controlled, but it may affect vaccine prioritization in other regions.

When a vaccine becomes available, our recommendations need to be reassessed to consider the eligibility of population subgroups based on the licensure label. They also need to be further reassessed periodically to account for changes in vaccine supply, demand and local epidemiology. Although we propose a general framework to define vaccination priorities, the proposed vaccination program needs to be tailored locally, accounting for country-specific contexts such the objectives of the pandemic responses, the local level of transmission, the make-up of first responders and essential workers as well as the capacity of immunization services.

Because of the high burden and limited capacity for vaccine production, we have highlighted that more attention should be paid to low-and-middle income countries. The WHO SAGE Working Group on COVID-19 Vaccines has been established in June, 2020 and includes an international team of experts. Their objectives include, but are not limited to, providing recommendations for early allocation of vaccines when vaccine supply is still constrained, and guidance on fair and equitable global access to vaccination. There is an urgent need for the WHO SAGE Working
Group to promote global cooperation on vaccine research and development, ensure vaccine production and supply, and speed up the development of guidelines for allocating and targeting COVID-19 pandemic vaccines. Our recommendations for mainland China could be used as a template for such guidelines.

Conclusions

Vaccine deployment is likely to become vitally important for the global response to the COVID-19 pandemic. Here we provide a general framework to define priority groups for a phased introduction of a universal COVID-19 vaccination program. We applied this framework to mainland China and further estimated the corresponding target population sizes. The proposed vaccination program could assist Chinese policy-makers in the roll-out of a large-scale immunization program and be used as a reference for other countries, especially in low-and-middle income regions. We recommend that the WHO SAGE Working Group on COVID-19 Vaccines takes the lead on making recommendations on priority target population for national/regional COVID-19 vaccination program, to ensure that all individuals, regardless of where they live, can benefit from a COVID-19 vaccine.

Methods

Goals of the COVID-19 vaccination program

The overarching goal of a vaccination program in the midst of such a pandemic, which can be characterized as having both very high transmissibility and clinical severity\(^\text{92}\), is to vaccinate all persons willing to be vaccinated. However, due to limited supplies, prioritization is warranted. The specific goal of COVID-19 vaccination in China could be determined in a phased approach, taking account 1) the interim framework for COVID-19 vaccine allocation and available guidance (e.g. from the US) on allocating vaccines during an influenza pandemic,\(^\text{12,13}\) 2) the objectives of and experience gained from the 2009 H1N1 pandemic vaccination program in China,\(^\text{93}\) 3) specific high-risk groups for severe COVID-19 outcomes, and 4) lessons learned from the response to the
COVID-19 outbreak in Wuhan such as the role of critical workers in sustaining essential societal functions\textsuperscript{1}. These goals should be adapted along with the evolving dynamic of the epidemic and an increase of vaccine supplies.

**Priority population groups for a COVID-19 vaccination program**

In line with the aforementioned goals of a COVID-19 vaccination program, we define population groups to be prioritized by occupation, age, and underlying conditions (Figure 1). Prioritization is based on utilitarian (i.e. maximizing health and economic benefit) and egalitarian (i.e. protecting the worst off) principles. Priority groups include: 1) essential workers, including but not limited to healthcare workers (utilitarian principles); 2) high-risk individuals such as those at the highest risk of severe/fatal outcomes (egalitarian principles); 3) individuals who play a key role in transmission (both utilitarian and egalitarian principles).\textsuperscript{94} Within the populations of interest for the primary and tertiary vaccination goals, the target population groups that met $\geq 2$ of the aforementioned principles were assigned to a higher tier. For the secondary goal, the target population at higher risk of severe/fatal COVID-19 outcome was assigned to a higher tier. Across priority population groups, vaccines can be allocated and administered according to tier, which means that all groups within a tier have equal priority for vaccination.

**Essential workers**

Individuals who are critical for preserving essential societal functions for public health and safety as well as the well-being of the community during a pandemic include: 1) first responders who may have close contact with potential COVID-19 patients in professional settings, including healthcare, public health, and community workers (these include staff in community service agencies, who maintain supply of daily essential needs for people under lockdown, and take routine prevention measures such as fever screening and environmental disinfection); 2) individuals who are essential for maintaining national security, namely individuals working in law enforcement agencies and security personnel (police and military); 3) workers maintaining...
production and supply of daily essentials, including energy, water, food, and transportation. The detailed definitions and their roles were presented in Supplementary Materials “More detailed methods.” We recommend these individuals to be an appropriate first-level priority target group for vaccination. We obtained the population size stratified by occupation from publicly available data, including the China Statistical Yearbook 2019, White Paper on China’s National Defense, and published literature.95,96

High-risk individuals

To meet the secondary goal of the vaccination program, individuals who are at increased risk for severe outcome of COVID-19 could be considered a priority target population for vaccination. We conducted a narrative literature review to identify the risk factors of severe illness associated with COVID-19. Clark and colleagues extracted the prevalence of underlying health conditions from the Global Burden of Diseases, Risk Factors, and Injuries Study (GBD), and estimated the number of people with at least one of these conditions in 2020 for 188 countries.97 Using Clark’s method, we updated the probability of having at least one of these conditions for China to additionally include the prevalence of BMI ≥30, which were identified as risk factors by our review. Then we estimated the age-specific population size of individuals with any of these conditions by multiplying the estimated probability by the UN mid-year population estimates for 2020 for China.98 The population size of individuals without these conditions was calculated subtracting those with health conditions from the total population. We estimated the number of women who are pregnant in one year as the sum of all live births, still births, fetal deaths, and abortions in that year. (Details in Supplementary Materials “More detailed methods”)

Individuals at high risks of symptomatic COVID-19 infections

A second narrative literature review was conducted to assess the risk of symptomatic COVID-19 infection (details in Supplementary Materials “More detailed methods”). Based on the identified risk factors for symptomatic COVID-19 infections, we defined the target populations for
vaccination that would help meet the tertiary goal of reducing illness. The populations size was obtained from UN mid-year population estimates for 2020 for China\textsuperscript{98}, and Ministry of Education of China\textsuperscript{99}.

Estimating size of target population of the phased universal vaccination program

First, we estimated the corresponding population size separately for each target population as mentioned above. When a person is included in more than one group, she/he is intended to be vaccinated in the highest tier group in which she/he is included. Accordingly, we then excluded people in more than one risk group to estimate the total population size stratified by goals of vaccination in different phases of the pandemic, and by vaccination tiers.

Further, we estimated the days needed to vaccinate 60\% of the targeted population in the sequence of Tiers given a two-dose vaccination schedule, without accounting for the production capacity (see schematic diagram in Supplementary Materials Figure S3). During the 2009 influenza pandemic, an average of 1.3 million daily doses of H1N1pdm vaccines were administered in China, reaching 3 million daily doses at the peak delivery date\textsuperscript{100}. In the baseline analysis, the maximum delivery capacity of the H1N1pdm vaccination service was used. Sensitivity analyses on the daily doses administered (1.3 million) and the uptake rates (80\%) were conducted. COVID-19 is more of a threat than H1N1pdm2009, and both the willingness to be vaccinated against COVID-19 as well as delivery capacity is likely to be greater\textsuperscript{101,102}, so we further assumed that the capacity of COVID-19 vaccination service could be scaled up to 6 million doses administered per day.
### Figure 1. Prioritized segments of the population for a COVID-19 vaccination program as well as estimated population size.
| Study                      | Cases | Total | Weight | Incidence (95%CI) per 100,000 | Incidence (95%CI) per 100,000 |
|----------------------------|-------|-------|--------|-------------------------------|-------------------------------|
| **Individuals aged <20 years** |       |       |        |                               |                               |
| Cruz CJP et al.            | 148   | 1,165,354 | 2.4%  | 12.7 [10.7; 14.9]            |                               |
| Robert Koch Institute      | 17,914| 15,611,520 | 2.5%  | 113.3 [111.6; 115.0]         |                               |
| National Health Service    | 10,471| 15,697,802 | 2.5%  | 66.7 [65.4; 68.0]            |                               |
| Stokes EK et al.           | 69,703| 82,003,529 | 2.6%  | 85.0 [94.4; 85.6]            |                               |
| BULLUT C et al.            | 741   | 8,923,702 | 2.6%  | 8.3 [7.7; 8.9]               |                               |
| COVID-19 NIRST             | 326   | 6,439,454 | 2.6%  | 5.1 [4.5; 5.6]               |                               |
| Jung C Y et al.            | 481   | 9,330,678 | 2.6%  | 5.2 [4.7; 5.6]               |                               |
| Gujski M et al.            | 536   | 13,400,000 | 2.6%  | 4.0 [3.7; 4.4]              |                               |
| Mazumder A et al.          | 87    | 7,260,000  | 2.6%  | 1.2 [1.0; 1.5]               |                               |
| Overall                    | 487,064,000 | 2.6% | 0.0 [0.0; 0.0]            |                               |
| Heterogeneity:             |       |       |        |                               |                               |
| Tau² = 0.1; Chi² = 100410.4; df = 9 (P = 0); I² = 100% |                               |

| **Individuals aged 20-39 years** |       |       |        |                               |                               |
| National Health Service     | 65,513| 17,316,598 | 2.3%  | 378.3 [375.4; 381.2]         |                               |
| Robert Koch Institute       | 62,896| 20,249,381 | 2.4%  | 310.8 [308.2; 313.0]         |                               |
| BULLUT C et al.             | 13,390| 9,968,580  | 2.4%  | 134.1 [131.8; 136.3]         |                               |
| Cruz CJP et al.             | 466   | 1,879,032  | 2.4%  | 24.8 [22.6; 27.2]            |                               |
| COVID-19 NIRST              | 2,529 | 7,093,798  | 2.5%  | 35.7 [34.3; 37.1]            |                               |
| Stokes EK et al.            | 397,318| 89,144,716 | 2.5%  | 445.7 [444.3; 447.1]         |                               |
| Jung C Y et al.             | 3,947 | 13,878,058 | 2.6%  | 28.4 [27.6; 29.3]            |                               |
| Pan A et al.                | 5,960 | 24,833,333 | 2.6%  | 24.0 [23.4; 24.6]            |                               |
| Gujski M et al.             | 349   | 10,906,250 | 2.6%  | 3.2 [2.9; 3.6]               |                               |
| Mazumder A et al.           | 502   | 455,538,000 | 2.6%  | 0.1 [0.1; 0.1]              |                               |
| Overall                     | 650,827,746 | 24.9% | 138.5 [94.8; 182.1]       |                               |
| Heterogeneity:             |       |       |        |                               |                               |
| Tau² = 0.1; Chi² = 554090.1; df = 9 (P = 0); I² = 100% |                               |

| **Individuals aged 40-59 years** |       |       |        |                               |                               |
| National Health Servicio    | 77,866| 17,641,941 | 2.2%  | 111.4 [108.3; 114.6]         |                               |
| Robert Koch Institute       | 71,265| 23,731,744 | 2.4%  | 300.3 [298.1; 302.5]         |                               |
| Stokes EK et al.            | 454,913| 83,266,891 | 2.5%  | 546.2 [544.6; 547.8]         |                               |
| COVID-19 NIRST              | 2,076 | 6,413,795  | 2.5%  | 32.4 [31.0; 33.8]            |                               |
| Cruz CJP et al.             | 250   | 2,293,578  | 2.5%  | 10.0 [9.6; 12.3]             |                               |
| Pan A et al.                | 12,269| 23,777,132 | 2.6%  | 51.6 [50.7; 52.5]            |                               |
| Jung C Y et al.             | 3,206 | 16,433,791 | 2.6%  | 19.5 [18.8; 20.2]            |                               |
| Gujski M et al.             | 435   | 10,357,143 | 2.6%  | 4.2 [3.8; 4.6]               |                               |
| Mazumder A et al.           | 360   | 297,792,000 | 2.6%  | 0.1 [0.1; 0.1]              |                               |
| Overall                     | 496,751,271 | 25.0% | 160.6 [107.9; 213.4]     |                               |
| Heterogeneity:             |       |       |        |                               |                               |
| Tau² = 0.1; Chi² = 654761.4; df = 9 (P = 0); I² = 100% |                               |

| **Individuals aged >60 years** |       |       |        |                               |                               |
| National Health Service     | 106,845| 16,677,863 | 2.1%  | 640.6 [636.8; 644.5]         |                               |
| Robert Koch Institute       | 60,519| 23,951,300 | 2.4%  | 252.3 [250.3; 254.3]         |                               |
| Stokes tK et al.            | 398,564| /2, /98,699 | 2.5%  | 546.4 [546.1; 549.4]         |                               |
| COVID-19 NIRST              | 2,144 | 5,552,834  | 2.5%  | 38.6 [37.0; 40.3]            |                               |
| Cruz CJP et al.             | 153   | 1,863,043  | 2.5%  | 9.2 [7.8; 10.8]              |                               |
| Pan A et al.                | 13,818| 16,372,038 | 2.5%  | 84.4 [83.0; 85.8]            |                               |
| Jung C Y et al.             | 2,603 | 11,864,454 | 2.6%  | 21.9 [21.1; 22.8]            |                               |
| Gujski M et al.             | 288   | 9,600,000  | 2.6%  | 3.0 [2.7; 3.4]               |                               |
| Mazumder A et al.           | 192   | 139,610,000 | 2.6%  | 0.1 [0.1; 0.2]              |                               |
| Overall                     | 310,623,881 | 24.5% | 194.9 [143.2; 246.7]    |                               |
| Heterogeneity:             |       |       |        |                               |                               |
| Tau² = 0.1; Chi² = 631432.4; df = 9 (P = 0); I² = 100% |                               |
| Overall                     | 2,105,288,937 | 100.0%| 124.6 [123.3; 125.8]      |                               |
| Heterogeneity:             |       |       |        |                               |                               |
| Tau² = 0.1; Chi² = 1,942,354.3; df = 39 (P = 0); I² = 100% |                               |

**Figure 2.** Pooled incidence of COVID-19 cases, stratified by age.
Figure 3. Estimated size of target population for the COVID-19 vaccination program by goal.

A: Overlap of target population groups. B: Estimated number of targeted individuals excluding the overlaps between groups. Note that m denotes million.
Figure 4. Estimated size of target population for the COVID-19 vaccination program by population group. A: number of individuals, B: proportion. Note that the overlaps between groups were excluded.
Figure 5. Days needed to vaccinate 60% of the target population, stratified by vaccination tier, under the assumption that three million doses are administered per day. Note that values reported within the square (e.g., 135.8m) denote 60% of the population size in each tier; m denotes million.
Acknowledgments

We thank Dr. Yang Liu from Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom for her comments to revise this article.

Funding

The study was supported by grants from the National Science Fund for Distinguished Young Scholars (No. 81525023), National Science and Technology Major Project of China (No. 2018ZX10201001-010, No. 2018ZX10713001-007, No. 2017ZX10103009-005), and the National Institute for Health Research (NIHR) (grant no. 16/137/109) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care.

Author Contributions

H.Y. conceived, designed and supervised the study. J.Y., W.Z., H.S., X.Y., K.D., Q.Y., G.Z., H.G. and Z.C. participated in data collection. J.Y., W.Z., H.S., X.Y., K.D., and Q.Y. analyzed the data, and prepared the tables and figures. J.Y. prepared the first draft of the manuscript. H.Y., M.J., C.V., and M.A. commented on the data and its interpretation, revised the content critically. All authors contributed to review and revision and approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Conflict of interest

H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. M.A. has received research funding from Seqirus. None of those research funding is related to
COVID-19. All other authors report no competing interests.
Reference

1. Li Z, Chen Q, Feng L, et al. Active case finding with case management: the key to tackling the COVID-19 pandemic. Lancet 2020; 396(10243): 63–70.
2. Draft landscape of COVID-19 candidate vaccines. August 12, 2020. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed August 12 2020).
3. Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nature reviews Drug discovery 2020.
4. ACT-Accelerator update. June 26, 2020. https://www.who.int/news-room/detail/26-06-2020-act-accelerator-update (accessed July 15 2020).
5. Coronavirus (COVID-19) Information and Updates. July 15, 2020 2020. https://www.coronavirustraining.org/live-map (accessed July 15 2020).
6. Pan A, Liu L, Wang C, et al. Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. JAMA 2020; 323(19): 1915–23.
7. July 15, 2020. http://www.beijing.gov.cn/English/ (accessed July 15 2020).
8. August 2, 2020. http://www.most.gov.cn/kjxx/qxydt/202008/t20200802_3250881.htm (accessed August 2 2020).
9. World’s Largest COVID-19 Vaccine Production Workshop Completed. May 15, 2020. http://en.sasac.gov.cn/2020/05/15/c_4885.htm (accessed July 15 2020).
10. CanSino sprints into the science and technology innovation board: The first share of the COVID-19 vaccine, the production capacity is planned to be 100-200 million doses. July 31, 2020 2020. https://baijiahao.baidu.com/s?id=1673689539936450558&wfr=spider&for=pc (accessed August 2 2020).
11. Zhifei Bio-Recombinant COVID-19 Vaccine Starts Clinical Trials Today. June 23, 2020 2020. http://finance.sina.com.cn/stock/relnews/cn/2020-06-23/doc-iirczymk8532722.shtml (accessed August 2 2020).
12. Interim updated planning guidance on allocating and targeting pandemic influenza vaccine during an influenza pandemic. July 24, 2020. https://www.cdc.gov/flu/pandemic-resources/pdf/2018-Influenza-Guidance.pdf (accessed July 24 2020).
13. Interim Framework for COVID-19 Vaccine Allocation and Distribution in the United States. August 10, 2020 2020. https://www.centerforhealthsecurity.org/our-work/pubs-archive/pubs-pdfs/20200819-vaccine-allocation.pdf (accessed August 10 2020).
14. Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetol 2020: 1-6.
15. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020; 12(7): 6049-57.
16. Xu L, Mao Y, Chen G. Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis. Aging (Albany NY) 2020; 12(12): 12410-21.
17. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male 2020: 1-9.
18. Li J, He X, Yuan Y, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) pneumonia. *AM J INFECT CONTROL* 2020.

19. Singh AK, Gillies CL, Singh R, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. *Diabetes Obes Metab* 2020.

20. Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. *Int J Public Health* 2020; 65(5): 533-46.

21. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Med Virol* 2020.

22. Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. *J Infect* 2020.

23. Giannakoulis VG, Papoutsi E, Siempos I. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data. *JCO Glob Oncol* 2020; 6(1): 799-808.

24. Wang X, Fang X, Cai Z, et al. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis. *Research (Washington, DC)* 2020; 2020: 2402961.

25. Taylor E, Hofmeyr R, Torborg A, Tonder CV, Anaesthesia BBJSAJo, Analgesia. Risk factors and interventions associated with mortality or survival in adult COVID-19 patients admitted to critical care: a systematic review and meta-analysis. *South Afr J Anaesth Analg* 2020; 26(3): 116-27.

26. Jutzeler CR, Bourguignon L, Weis CV, et al. Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis. *Travel Med Infect Dis* 2020: 101825.

27. Fang X, Li S, Yu H, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. *Aging (Albany NY)* 2020; 12(13): 12493-503.

28. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. *Aging Dis* 2020; 11(3): 668-78.

29. Aggarwal G, Cheruiyot I, Aggarwal S, et al. Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis. *Curr Probl Cardiol* 2020; 45(8): 100617.

30. Pranata R, Lim MA, Yonas E, et al. Body Mass Index and Outcome in Patients with COVID-19: A Dose-Response Meta-Analysis. *Diabetes Metab* 2020.

31. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. *Diabetes Metab Syndr* 2020; 14(4): 395-403.

32. Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes Metab Syndr* 2020; 14(4): 535-45.

33. Nandy K, Salunke A, Pathak SK, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. *Diabetes Metab Syndr* 2020; 14(5): 1017-25.

34. Wu J, Zhang J, Sun X, et al. Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 (COVID-19) infection. *Diabetes Obes Metab* 2020.
35. Guo L, Shi Z, Zhang Y, et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis. *Diabetes Res Clin Pract* 2020; **166**:108346.

36. Parveen R, Sehar N, Bajpai R, Agarwal NB. Association of diabetes and hypertension with disease severity in covid-19 patients: A systematic literature review and exploratory meta-analysis. *Diabetes Res Clin Pract* 2020; **166**:108295.

37. Ofori-Asenso R, Ogundipe O, Agyeman AA, et al. Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis. *Ecancermedicalscience* 2020; **14**:1047.

38. Zhang J, Wu J, Sun X, et al. Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. *Epidemiol Infect* 2020; **148**:e106.

39. Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of Adverse Prognosis in Covid-19: A Systematic Review and Meta-analysis. *Eur J Clin Invest* 2020: e13362.

40. Li X, Guan B, Su T, et al. Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. *Heart* 2020; **106**(15):1142-7.

41. Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. *Hepatol Int* 2020: 1-9.

42. Tian Y, Qiu X, Wang C, et al. Cancer associates with risk and severe events of COVID-19: A systematic review and meta-analysis. *International journal of cancer* 2020.

43. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis* 2020; **94**: 91-5.

44. Zhou Y, Yang Q, Chi J, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. *Int J Infect Dis* 2020.

45. Zhao J, Li X, Gao Y, Huang W. Risk factors for the exacerbation of patients with 2019 Novel Coronavirus: A meta-analysis. *Int J Med Sci* 2020; **17**(12): 1744-50.

46. Aggarwal G, Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Diabetes Mellitus Association with Coronavirus Disease 2019 (COVID-19) Severity and Mortality: A Pooled Analysis. *Journal of diabetes* 2020.

47. Lu L, Zhong W, Bian Z, et al. A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis. *J Infect* 2020.

48. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: a systematic review and meta-analysis. *J Med Virol* 2020.

49. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. *J Med Virol* 2020.

50. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association* 2020; **29**(8): 104949.

51. Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. *Nutr Metab Cardiovasc Dis* 2020; **30**(8): 1236-48.
52. Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. *Obes Res Clin Pract* 2020.

53. Földi M, Farkas N, Kiss S, et al. Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis. *Obesity reviews : an official journal of the International Association for the Study of Obesity* 2020.

54. Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. *PloS one* 2020; 15(5): e0233147.

55. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. *Pol Arch Intern Med* 2020; 130(4): 304-9.

56. Deng M, Ye M, Xiao X, et al. Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis. *Aging and disease* 2020; 11(4).

57. Wu X, Liu L, Jiao J, Yang L, Zhu B, Li X. Characterisation of clinical, laboratory and imaging factors related to mild vs. severe covid-19 infection: a systematic review and meta-analysis. *Annals of medicine* 2020: 1-11.

58. Hariyanto TI, Kurniawan A. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. *Diabetes Metab Syndr* 2020; 14(5): 1463-5.

59. Salunke AA, Nandy K, Pathak SK, et al. Impact of COVID-19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis. *Diabetes Metab Syndr* 2020; 14(5): 1431-7.

60. ElGohary GM, Hashmi S, Styczynski J, et al. The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. *Hematology/Oncology and Stem Cell Therapy* 2020.

61. Liu M, Gao Y, Shi S, Chen Y, Yang K, Tian J. Drinking no-links to the severity of COVID-19: a systematic review and meta-analysis. *J Infect* 2020; 81(2): e126-e7.

62. Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis. *J Med Virol* 2020.

63. Patel U, Malik P, Shah D, Patel A, Dhamoon M, Jani V. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. *J Neurol* 2020; 1-8.

64. Siepmann T, Sedghi A, Barlinn J, et al. Association of history of cerebrovascular disease with severity of COVID-19. *J Neurol* 2020.

65. Sales-Peres SHC, de Azevedo-Silva LJ, Bonato RCS, Sales-Peres MC, Pinto A, Santiago Junior JF. Coronavirus (SARS-CoV-2) and the risk of obesity for critically illness and ICU admitted: Meta-analysis of the epidemiological evidence. *Obes Res Clin Pract* 2020.

66. Sanchez-Ramirez DC, Mackey D. Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: A systematic review and meta-analysis. *Respir Med* 2020; 171: 106096.

67. Pastick KA, Nicol MR, Smyth E, et al. A Systematic Review of Treatment and Outcomes of Pregnant Women with COVID-19 – A Call for Clinical Trials. *Open Forum Infectious Dis* 2020.

68. Panahi L, Amiri M, Pouy S. Risks of Novel Coronavirus Disease (COVID-19) in Pregnancy; a Narrative Review. *Arch Acad Emerg Med* 2020; 8(1): e34.

69. People who are at higher risk for severe illness. June 25, 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-increased-risk.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-
70. Liu M, Gao Y, Zhang Y, Shi S, Chen Y, Tian J. The association between severe or dead COVID-19 and autoimmune diseases: A systematic review and meta-analysis. *J Infect* 2020.
71. Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. *J Infect* 2020; 81(2): e93–e5.
72. Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. *Nat Med* 2020; 26: 506–10.
73. Banerjee A, Pasea L, Harris S, et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. *Lancet* 2020; 395(10238): 1715–25.
74. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22–May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69(24): 759–65.
75. Zhang J, Klepac P, Read JM, et al. Patterns of human social contact and contact with animals in Shanghai, China. *Sci Rep* 2019; 9(1): 15141.
76. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet* 2020.
77. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet* 2020.
78. Davies NG, Klepac P, Liu Y, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med* 2020.
79. Zhang J, Litvinova M, Liang Y, et al. The impact of relaxing interventions on human contact patterns and SARS-CoV-2 transmission in China. *MedRxiv*. https://www.medrxiv.org/content/10.1101/2020.08.03.20167056v1 (accessed.
80. Hu S, Wang W, Wang Y, et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. *MedRxiv*, 2020. https://www.medrxiv.org/content/medrxiv/early/2020/08/07/2020.07.23.20160317.full.pdf (accessed.
81. Szablewski CM, Chang KT, Brown MM, et al. SARS-CoV-2 Transmission and Infection Among Attendees of an Overnight Camp - Georgia, June 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69(31): 1023–5.
82. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection amongst children and adolescents compared with adults: a systematic review and meta-analysis. *MedRxiv*, 2020. https://www.medrxiv.org/content/10.1101/2020.05.20.20108126v2 (accessed.
83. Zhang J, Litvinova M, Liang Y, et al. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science* 2020; 368(6498): 1481–6.
84. Poletti P, Tirani M, Cereda D, Trentini F. Probability of symptoms and critical disease after SARS-CoV-2 infection. *arXiv*. https://arxiv.org/abs/2006.08471 (accessed.
85. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet* 2020; 395(10239): 1771–8.
86. Waltenburg MA, Victoroff T, Rose CE, et al. Update: COVID-19 Among Workers in Meat and Poultry Processing Facilities - United States, April-May 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69(27): 887–92.
87. Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-
19 death in 17 million patients. *Nature* 2020.

88. Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of COVID-19? *BMJ* 2020; 369: m1548.

89. Are some ethnic groups more vulnerable to COVID-19 than others? July 15, 2020. [https://web.archive.org/web/20200502130148/https://www.ifs.org.uk/inequality/chapter/are-some-ethnic-groups-more-vulnerable-to-covid-19-than-others/](https://web.archive.org/web/20200502130148/https://www.ifs.org.uk/inequality/chapter/are-some-ethnic-groups-more-vulnerable-to-covid-19-than-others/) (accessed July 15 2020).

90. Zheng Y, Rodewald L, Yang J, et al. The landscape of vaccines in China: history, classification, supply, and price. *BMC Infect Dis* 2018; 18(1): 502.

91. WHO Working Group – Vaccine R&D for COVID-19 Vaccines. April 17, 2020. [https://www.who.int/publications/m/item/who-working-group-vaccine-r-d-for-covid-19-vaccines](https://www.who.int/publications/m/item/who-working-group-vaccine-r-d-for-covid-19-vaccines) (accessed July 15 2020).

92. Freitas ARR, Napimoga M, Donalisio MR. Assessing the severity of COVID-19. *Epidemiol Serv Saude* 2020; 29(2): e2020119.

93. Guidance on 2009 influenza pandemic vaccination programme in China. September 23, 2019. [http://www.gov.cn/zwgk/2009-09/23/content_1424257.htm](http://www.gov.cn/zwgk/2009-09/23/content_1424257.htm) (accessed July 26 2020).

94. Zimmerman RK. Rationing of influenza vaccine during a pandemic: ethical analyses. *Vaccine* 2007; 25(11): 2019–26.

95. China Statistical Yearbook 2019. July 15, 2020. [http://www.stats.gov.cn/tjsj/ndsj/2019/indexch.htm](http://www.stats.gov.cn/tjsj/ndsj/2019/indexch.htm) (accessed July 15 2020).

96. White paper. July 24, 2019. [http://www.scio.gov.cn/zfbps/32832/Document/1660314/1660314.htm](http://www.scio.gov.cn/zfbps/32832/Document/1660314/1660314.htm) (accessed July 15 2020).

97. Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *Lancet Glob Health* 2020.

98. UN population 2020. July 15, 2020. [https://population.un.org/wpp/Download/Standard/Population/](https://population.un.org/wpp/Download/Standard/Population/) (accessed July 15 2020).

99. Ministry of Education of China. Statistics Yearbook of Education in 2019. [http://www.moe.gov.cn/s78/A03/moe_560/jytjsj_2019/qg/](http://www.moe.gov.cn/s78/A03/moe_560/jytjsj_2019/qg/) Accessed August 12, 2020.

100. Report of H1N1 pandemic influenza vaccination from Ministry of Health. July 15, 2020. [http://www.gov.cn/gzdt](http://www.gov.cn/gzdt). (accessed July 15 2020).

101. Seale. H, Kaur. R, Wang Q. Acceptance of a vaccine against pandemic influenza A (H1N1) virus amongst healthcare workers in Beijing, China. *Vaccine* 2011; 29: 1605-10.

102. Fu C, Wei Z, Pei S, et al. Acceptance and preference for COVID-19 vaccination in healthcare workers (HCWs). medRxiv preprint doi: [https://doi.org/10.1101/2020.04.09.20060103](https://doi.org/10.1101/2020.04.09.20060103).